Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infant pneumococcal conjugate vaccine schedule and product comparison
ISRCTN17673117Phase 4Recruiting
- Sponsor
- University of Oxford
- Start
- Dec 2024
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
01
Overview
Phase 4, randomised, open-label trial of pneumococcal conjugate vaccine, Prevnar 20 and Prevnar 13 in pneumococcal disease (7 arms), sponsored by University of Oxford. Primary endpoint: PCV13 serotype-specific serum IgG concentration. Started Dec 2024; status: recruiting.
02
Drugs
pneumococcal conjugate vaccinePrevnar 20Prevnar 13
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on ISRCTN17673117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN17673117.